Ezra E.W. Cohen, MD, on Head and Neck Cancer: Avelumab and Chemoradiotherapy in Locally Advanced Disease
ESMO Virtual Congress 2020
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses primary results of the phase III JAVELIN trial of locally advanced squamous cell carcinoma of the head and neck, in which the immune checkpoint inhibitor avelumab was combined with chemoradiotherapy followed by avelumab maintenance. Although the study results were negative, Dr. Cohen suggests other regimens that may prove to be effective (Abstract 910O).
The ASCO Post Staff
Cécile Le Pechoux, MD, of the Institut Gustave Roussy, discusses new findings from an international trial on an old controversy: What is the role of postoperative radiotherap...
The ASCO Post Staff
Stephen R.D. Johnston, MD, PhD, of The Royal Marsden NHS Foundation Trust, discusses phase III study findings from the global monarchE trial, which showed that when added to ...
The ASCO Post Staff
Sumanta K. Pal, MD, of the City of Hope National Medical Center, discusses results from the COSMIC-021 study, which tested two different doses of cabozantinib, each with a st...
The ASCO Post Staff
Monika K. Krzyzanowska, MD, MPH, of the Princess Margaret University Health Network, discusses study findings on remote proactive telephone-based toxicity management for patients w...
The ASCO Post Staff
Mansoor Raza Mirza, MD, of Copenhagen University Hospital, discusses phase II study results that showed the combination of palbociclib and letrozole, compared with placebo pl...
